Futibatinib not checked
Taiho · TAS-120 · TAS-120 + fulvestrant
FollowEvery change as it happens, and a Monday email
Trials
9 active
15 in total · 9 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
- How it’s given
- “TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.”In the company’s words, NCT04999761 on ClinicalTrials.gov
- Tested for
- Biliary Tract Cancer (2 trials), Advanced/Metastatic Cancer, Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer, Advanced Cholangiocarcinoma and 10 more
- Main trialPhase 3
- “To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer”In the company’s words, NCT07710885 on ClinicalTrials.gov
- Other names
- TAS-120 · TAS-120 + fulvestrant
Other drugs for Biliary Tract Cancer
- Trastuzumab deruxtecanDaiichi Sankyo · AstraZeneca · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- CTX-009Compass Therapeutics · Phase 2/3
- RilvegostomigAstraZeneca · Phase 3
- NanvuranlatJ-Pharma Co., Ltd. · Phase 3
- DurvalumabAstraZeneca · Phase 3
Coming up4
- DecPhase 2 trial completes · ClinicalTrials.gov
- Apr 2027Phase 2/3 trial completes · ClinicalTrials.gov
- Jun 2027Phase 1 trial completes · ClinicalTrials.gov
- 30 Apr 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials15
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Apr 2030 | Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer | |
| Phase 2/3Active, not recruiting | Apr 2027 | Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | |
| Phase 2Active, not recruiting | 1 Oct 2026 | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | |
| Phase 2Recruiting | Dec 2026 | Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | |
| Phase 1Recruiting | Jun 2027 | AB122 Platform Study | |
| Phase 3Terminated | 22 Apr 2024 | Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | |
| Phase 2Terminated | 31 May 2023 | A Study of TAS-120 in Patients With Metastatic Breast Cancer | |
| Phase 2Terminated | 8 Mar 2024 | Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma | |
| Phase 2Terminated | 11 Nov 2024 | Futibatinib in Patients With Specific FGFR Aberrations | |
| Phase 1/2Completed | 1 Oct 2020 | A Study of TAS-120 in Patients With Advanced Solid Tumors | |
| Phase 3Authorised | not given | SAFIR ABC10 : Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, platform phase 3 trial | |
| Phase 2Authorised | not given | Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours | |
| Phase 1/2Authorised | not given | AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | |
| Phase 3Ended | not given | MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study | |
| Phase 2Authorised | not given | FUTURE platform trial – A phase II platform trial of futibatinib in combination with (chemo)immunotherapy in colorectal cancer and other solid tumor entities |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026